F. Y. Feng

This study identifies non-coding regulatory regions driving metastatic prostate cancer using an integrative computational and experimental approach.

This paper evaluates CDCP1 as a target for radioligand therapy in mCRPC, showing its expression in most biopsies and demonstrating antitumor effects with 177Lu-4A06.

This study uses single-cell RNA-sequencing to analyze prostate cancer tumor microenvironment, identifying heterogeneous epithelial cell states and tumor-associated club cells.

The paper functionally maps AR enhancer activity using STARRseq, finding most AR binding sites are inactive or constitutively active, with inducible enhancers forming regulatory hubs that drive gene transcription.

The paper identifies three macrophage subtypes in human prostate cancer using single-cell transcriptomics and develops a gene signature linked to patient survival.

This study characterizes the autoantibody landscape in metastatic castration-resistant prostate cancer using serum epitope repertoire analysis and identifies novel tumor-specific epitopes.